Furthermore, cancer–nerve crosstalk was found to represent a mechanism by which loss of p53 function drives reprogramming of tumor-associated neurons toward an adrenergic phenotype that stimulates tumor progression, and thus can be a potential target for anticancer therapy (44). This evidence concerns the gene TP53 and neoplasm.